Sir, Many relatively solvent-tolerant bacteria, notably species of Pseudomonas, are capable of extruding organic solvent via energy-dependent efflux systems, thus reducing their intracellular concentration below toxic levels. 1, 2 Some reports suggest that organic solvent tolerance (OST) and antibacterial resistance are positively correlated since the widely studied multisubstrate AcrAB efflux pump can extrude many unrelated antibacterials as well as organic solvents. 1 -5 It has been hypothesized, therefore, that OST might be an indicator of efflux pump activity associated with resistance to fluoroquinolones and other antimicrobials. 2 However, while Schneiders et al. 6 found that 10 of 19 fluoroquinolone-resistant clinical isolates of Klebsiella pneumoniae were tolerant to cyclohexane, they found no correlation between OST and fluoroquinolone MICs.
In order to test the hypothesis that OST can predict fluoroquinolone resistance and possibly efflux pump activity, the present study investigated the association between OST and ciprofloxacin susceptibility amongst 75 distinct clinical isolates of K. pneumoniae with varying ciprofloxacin MICs, and a K. pneumoniae reference strain. The MICs of ciprofloxacin for these 76 strains were determined by the agar dilution method described by the BSAC guidelines.
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The isolates were tested for OST using a modification of the method of White et al. 4 with the organic solvents hexane, cyclohexane and their mixtures. Isolates were cultured to midlogarithmic phase in Luria -Bertani (LB) broth, spotted on to LB agar, allowed to dry, overlaid with 2 -3 mm of organic solvent/mixture and incubated for 72 h at 218C in a fume cabinet. A confluent bacterial growth within a spot was considered OST positive and no growth OST negative. OST was tested at five arbitrary levels of toxicity (see Figure 1) . Growth in hexane alone (the least toxic) 4 was given a score of 1, and growth in increasingly toxic solvents/mixtures of 75% hexane/ 25% cyclohexane, 50% hexane/50% cyclohexane, 25% hexane/ 75% cyclohexane and 100% cyclohexane was given scores of 2, 3, 4 and 5, respectively. All experiments were performed in duplicate and gave the same results.
The association between OST and ciprofloxacin MICs was determined by using Pearson's correlation coefficient analysis.
The 75 K. pneumoniae clinical isolates and the reference strain had ciprofloxacin MICs ranging from 0.06 to .512 mg/L and included 10 -25 isolates within each of the ciprofloxacinsusceptible, reduced susceptible, moderately resistant and highly resistant groups. The relatively large number of isolates with a wide range of ciprofloxacin susceptibilities provided a better assessment of the association between ciprofloxacin MICs and OST than was possible with the study of Schneiders et al., Twenty-one of the 76 isolates were tolerant to hexane alone and 21 were tolerant to cyclohexane, hexane and their mixtures; 8 were fully susceptible to hexane, cyclohexane and to the mixtures of hexane and cyclohexane; and 26 showed varying degrees of tolerance to the mixtures. The tolerance scores ranged between 1 and 5. The reference K. pneumoniae isolate was tolerant only to hexane, the less toxic of the two solvents used. Figure 1 shows that there was no correlation between ciprofloxacin MICs and OST amongst the 76 isolates (correlation coefficient 20.01). Schneiders et al. 6 had similar results to ours in a smaller study. Therefore the OST phenotype is not a reliable indicator of fluoroquinolone resistance or of possible fluoroquinolone efflux phenotype in K. pneumoniae.
Other studies 2 -5 have reported a positive correlation between OST and antimicrobial resistance in other bacterial species. This may have been due to a bias of investigating mainly antibacterial-resistant isolates rather than using both susceptible and resistant ones, and to testing only a small number of strains. There may also be differences in the physiology of different bacterial species and the mechanisms of resistance to different antimicrobials.
Ciprofloxacin susceptibility in the Enterobacteriaceae can be affected by a number of resistance mechanisms including target site alterations, efflux pump activity, outer membrane-mediated drug resistance, fluoroquinolone target protection-mediated resistance and fluoroquinolone modification-associated mechanisms. The most significant mechanism is target site alteration due to mutations in the quinolone resistance-determining region (QRDR). Isolates often also express varying degrees of efflux pump activity. Pump activity on its own usually produces relatively low-level ciprofloxacin resistance but can have an additive effect when combined with target site mutational resistance mechanisms. However, when target site alterations produce high-level ciprofloxacin resistance, the presence of efflux pump activity may not raise the ciprofloxacin MIC further. This may be one explanation for why OST is not correlated with ciprofloxacin MICs in highly resistant strains. However, there is another possible more general reason for this lack of correlation across a range of ciprofloxacin MICs. OST phenotypes are thought to be primarily mediated by membrane-associated factors such as membrane impermeability and efflux pumps. 1 -3,5 Hydrocarbon solvents such as hexane and cyclohexane are hydrophobic while ciprofloxacin is amphipathic. Bacteria employ different protective mechanisms to counteract the deleterious effects of these two different classes of compound. It is not surprising, therefore, that tests for tolerance to hydrophobic organic solvents may not identify efflux systems also effective against largely hydrophilic antimicrobials such as ciprofloxacin. This may be the explanation for the results of this study, which showed that many ciprofloxacin-susceptible isolates were highly tolerant to organic solvents and vice versa (Figure 1 ).
In conclusion, this study demonstrates that OST phenotype is not a reliable indicator of fluoroquinolone resistance or of possible antimicrobial efflux phenotype in Enterobacteriaceae. Sir, The WHO has identified tuberculosis as the leading cause of death in HIV-positive patients, accounting for 13% of AIDS deaths worldwide. 1 Effective treatment for mycobacterial and HIV co-infection represents a major public health challenge.
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